Most anti-aging products target visible symptoms rather than cellular senescence, a process linked to declining skin function
R&D Focus
Longevity peptides, senescent-cell biology, AI screening and biological-age measurement
Innovative Solution
OS-01 is a proprietary peptide selected through screening and evaluated with OneSkin’s MolClock biological-age model
Solution Effectiveness
Company and published materials report a 2.5-year reduction in measured skin biological age and about 40% greater epidermal thickness in a five-day ex vivo model
Investment Funding
Last Funding Stage
Seed
Total Funding Amount
$14.6M
Last Funding Amount
$12.4M
Last Funding Date
10/26/2022
Startup Stage
Early Stage
Lead Investors
Metaplanet Holdings, Selva Ventures, West (San Francisco), 2Future Holdings, Karen Moon
People
Founders
Carolina Oliveira Ph.D
Amanda Guimarães
Alessandra Zonari Ph.D
Mariana Boroni Ph.D
Juliana Carvalho
CEO
Carolina Oliveira
About
Oneskin is a provider of a topical skin supplement intended to target the root causes of skin aging
Products
Product
OS-01 FACE, BODY and related longevity skincare; customer reviews are available on the official site
Star Product
OS-01 FACE, the flagship product carrying the core longevity-peptide claim
Demo Product or Complete Product?
Complete commercial line, including OS-01 FACE and BODY products
Future Plan
Market Expansion
The 2025 Series A was positioned to support U.S. growth and expansion in Asia
Investment Funding
$20M Series A reported in August 2025
Awards and Recognitions
Awards
Fast Company Most Innovative Companies, Beauty category, 2024
Media Apperance
Covered by Vogue Business, longevity and beauty media
M&A and Collabs
Collab
L’Oréal BOLD participated in the Series A funding round
Collab
EDBI participated in the Series A, supporting international growth
Something missing or incorrect on this page? Help us enrich this information
